Dexafort

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dexafort

Property Description
Active ingredient Dexamethasone (Dual-ester formulation)
Form Suspension for Injection
Pharmacological class Glucocorticoid (Corticosteroid)
General purpose Anti-inflammatory and Anti-allergic agent
Origin Synthetic

What Type of Medicine is Dexafort?

Dexafort is a potent, synthetic veterinary medicinal product whose active substance is Dexamethasone, which is pharmacologically recognized as a highly effective glucocorticoid within the broad category of corticosteroids. This preparation is a fluorinated steroid designed to mimic and enhance the effects of natural steroid hormones produced in the body. Dexamethasone possesses potent glucocorticosteroid activity with minimal influence on mineral balance, which substantiates its regulatory influence over the body’s metabolic and inflammatory processes.

Composition and Unique Formulation

The active ingredient in Dexafort is Dexamethasone, uniquely presented as a dual-ester formulation in an Aqueous Suspension for Injection. This specialized composition strategically combines Dexamethasone sodium phosphate for rapid onset of activity and Dexamethasone phenylpropionate for a prolonged duration of activity. This unique approach facilitates immediate and sustained relief from a single intramuscular administration.

General Purpose: Anti-inflammatory and Anti-Allergic Role

The primary function of Dexafort is to serve as a powerful systemic anti-inflammatory and anti-allergenic agent. It employs its glucocorticoid effects to suppress undesirable inflammation and mitigate exaggerated reactions of the body's defensive systems. Dexafort is often used in situations requiring rapid and sustained control over inflammatory episodes, such as managing acute allergic reactions or controlling severe joint inflammation. By dampening the inflammatory and anti-allergenic pathways, the medicine's general purpose is to provide relief from acute discomfort, heat, and tissue swelling associated with various inflammatory processes.

What side effects are possible with Dexafort?

Possible Side Effects and Safety Information

The safety profile for Dexamethasone, the active ingredient in Dexafort, is defined by systemic effects documented across several physiological systems. The occurrence and severity of potential adverse reactions are highly dependent on the dose and duration of exposure, as noted in official regulatory documents.

Documented Adverse Reaction Categories

Adverse reactions are officially listed across key system-organ classes, including Endocrine Disorders (suppression of adrenal function), Metabolism and Nutrition Disorders (potential for inducing diabetes mellitus), Gastrointestinal Disorders (risk of ulceration), and Musculoskeletal Disorders (muscle atrophy and weakness).

Reactions classified as common or expected, particularly during the initial phase of systemic therapy, include increased water intake (polydipsia) and increased urination (polyuria). Severe effects, such as iatrogenic hypercorticism, are typically associated with long-term or repeated administration and are documented as very rare.

Serious Adverse Reactions and Population-Specific Constraints

Official regulatory information highlights several serious adverse reactions, particularly concerning specific animal groups. The use of this medicine in horses carries a specific, documented risk of inducing laminitis. Furthermore, administration to cattle during the late stage of gestation carries the risk of inducing abortion or premature parturition, which can lead to complications such as retained placenta.

Safety-related constraints also define limitations on its use. The medicine is generally restricted or requires caution in animals with pre-existing conditions such as diabetes mellitus, renal insufficiency, congestive heart failure, and existing gastrointestinal ulcers. Due to the immunosuppressant nature of glucocorticoids, regulatory texts also note the potential for these medicines to mask the clinical signs of infection.

Overdose and Emergency Response

Overdose and when to seek help

Overexposure to Dexamethasone, the active ingredient in Dexafort, is officially documented as primarily involving an exaggeration of known systemic glucocorticoid effects. Acute manifestations include severe fluid and electrolyte disturbances, such as hypokalemic alkalosis and hypertension, alongside hyperglycemia and serious psychic disturbances. Chronic or repeated misuse is associated with the potential development of a Cushingoid state.

Officially Documented Severe Outcomes

Severe outcomes cited in regulatory information include life-threatening events that require urgent care. These may involve the cardiovascular system, such as cardiac arrest and circulatory collapse, or serious complications like peptic ulceration with potential hemorrhage or perforation. Overexposure may also lead to increased intracranial pressure in some cases. Individuals with cirrhosis may experience an enhanced effect due to decreased clearance.

When to Seek Urgent Medical Help

Official regulatory documents mandate that for any suspected overexposure, individuals seek immediate medical attention or contact a Poison Control Center. This action is required due to the potential for severe, acute physiological crises. Management of overexposure is limited to symptomatic and supportive treatment and continuous monitoring of vital signs, as no specific antidote is known. The treatment focuses on correcting the documented physiological imbalances, such as fluid and electrolyte status.

Therapeutic Uses of Dexafort

What Dexafort Treats: Main Uses and Benefits

The primary role of Dexafort is to support symptomatic relief across several key therapeutic domains in horses, cattle, dogs, and cats. Its dual-ester formulation is commonly used in clinical settings that involve acute or disruptive symptom patterns where short-term symptomatic assistance is appropriate.


Relief for Acute Inflammatory and Allergic Symptoms

This medicine is commonly used across conditions presenting with acute episodes or recurrent manifestations that create noticeable functional strain, such as musculoskeletal disorders and severe allergic reactions. It is relevant for managing symptoms related to inflammatory or irritative states. It helps address symptom clusters that may become intense or disruptive, which contributes to improved comfort during phases of heightened symptoms.

“It is applied during phases where symptoms become more noticeable, contributing to easing the overall symptom load.”

Metabolic and Systemic Support

Dexafort is commonly used across conditions presenting with acute episodes, specifically for the treatment of primary ketosis (acetonaemia) in cattle, which involves symptoms related to systemic imbalance. By assisting in the management of symptoms related to systemic imbalance, it contributes to improved comfort when symptoms are more noticeable. It may also be part of symptomatic management in acute systemic crises, providing supportive relief in conjunction with primary treatment.

Brief Listing of Indications: The medication is commonly used to help with conditions presenting with systemic or localized discomfort, such as arthritis, bursitis, tendinitis, allergic dermatitis, mastitis, metritis, shock, and the specific metabolic condition of ketosis in cattle.

Therapeutic Context for Acute Discomfort
Dexafort provides supportive relief when symptoms interfere with routine activities, helping patients cope more steadily with symptom fluctuations.

Regulatory References

  1. UK Veterinary Medicines Directorate

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Dexafort?

Regulatory documents define population eligibility for Dexafort strictly by species, pre-existing conditions, infectious status, and reproductive state. The product is approved for use only in the target species: Horses, Cattle, Dogs, and Cats.

Populations for Whom Use is Contraindicated

Use is formally contraindicated, except in emergency situations, in animals suffering from the following conditions:

  • Metabolic: Diabetes mellitus or hyperadrenocorticism (Cushing's syndrome).
  • Organ/System: Chronic nephritis or renal disease, congestive heart failure, and osteoporosis.
  • Infectious: Viral infections during the viraemic stage or systemic fungal infections.

Eligibility-Related Restrictions

Pregnancy Status: Corticosteroids are not recommended for use in pregnant animals due to the potential for foetal abnormalities or abortion. The sole exception is the specific labeled use for inducing parturition in cattle late in pregnancy.

Age: Special caution is required for use in young, growing animals due to documented risks concerning growth and bone development. Use in horses requires close observation due to the risk of inducing or worsening laminitis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dexafort, a glucocorticoid, has documented interaction patterns that are essential to review before co-administration with other medicines or products. The official regulatory profile organizes interactions based on potential risk and effect modification.

High-Risk and Restricted Combinations

Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is officially restricted because this combination significantly increases the risk of gastrointestinal ulcers and perforation. The use of live or live attenuated vaccines must be avoided in patients receiving immunosuppressive doses of the corticosteroid due to the potential for reduced immune response.

Interactions Altering Drug Levels

The metabolism of Dexamethasone is mediated by the CYP3A4 enzyme system. Co-administration with enzyme inducers such as Phenytoin or Rifampin may enhance the clearance of Dexamethasone, leading to a reduced therapeutic exposure. Conversely, enzyme inhibitors like Ketoconazole or Erythromycin can decrease Dexamethasone metabolism, which may result in increased plasma concentrations.

Pharmacodynamic and Specific Interactions

Dexamethasone’s inherent effects may be reinforced by other medicines. Co-administration with potassium-depleting diuretics can increase the risk of hypokalemia. The drug may also reduce the intended effect of Anti-diabetic agents and Coumarin-type anticoagulants. Additionally, Dexamethasone clearance is decreased in patients with chronic hepatic impairment (cirrhosis), which can lead to an enhanced corticosteroid effect.

Mechanism of Action

Dexafort, containing dexamethasone phosphate and dexamethasone phenylpropionate, is an agonist of the intracellular glucocorticoid receptor ( GR).

Following cell entry, the dexamethasone moiety binds to the cytoplasmic GR, causing complex dissociation from chaperone proteins. This ligand-receptor complex translocates into the cell nucleus, where it functions as a transcription factor.

This genomic mechanism involves two primary intracellular pathways: transactivation and transrepression. Via transactivation, the complex binds to glucocorticoid response elements ( GREs) on DNA, upregulating the transcription of anti-inflammatory genes, such as those encoding Annexin-A1 ( Lipocortin-1). Annexin-A1 then acts as an inhibitor of Phospholipase A2 ( PLA2), suppressing the release of arachidonic acid and the subsequent synthesis of pro-inflammatory eicosanoids (prostaglandins and leukotrienes).

Concurrently, transrepression occurs through direct protein-protein interaction, where the GR complex inhibits the activity of key pro-inflammatory transcription factors, such as Nuclear Factor-kappa B ( NF-kappa B). This downstream cascade results in the downregulation of gene expression for pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-alpha), chemokines, and cyclooxygenase-2 ( COX-2). System-level physiological consequences include generalized vascular permeability modulation and leukocyte migration inhibition, resulting in a broad dampening of tissue inflammation and immune responses.

Dosage and Administration Information

Administration Scope

The administration of Dexafort is defined by its formulation as an Aqueous Suspension for Injection containing a combination of Dexamethasone esters. This dual-ester structure, which ensures both rapid and prolonged activity, dictates the overall dosing pattern. The medicine is administered through several distinct injection routes, including systemic administration via Intramuscular (IM) or Intravenous (IV) injection, and localized administration, such as Intra-articular injection into joint spaces or injection into surrounding soft tissues.

Dosing and Frequency Schedule

The regimen is designed around a characteristic single administration for a course of treatment. The duration of action provided by the formulation means repeat dosing is not typically required, but may be considered based on clinical necessity after an interval of approximately 6 to 8 days. The milligram dose is determined by the species; for instance, the typical range for cattle is 10 mg to 20 mg, while horses are administered 5 mg to 15 mg.

Preparation and Procedural Conditions

Prior to administration, the suspension requires specific handling: the liquid must be shaken well immediately before being measured and injected to ensure the fast-acting and long-acting components are uniformly distributed. For systemic use, the product is delivered deep intramuscularly, whereas for localized use, it is injected directly into the designated site, always following aseptic procedural techniques. This single-dose, interval-based use pattern characterizes the administration conditions.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in the Common Cold

The majority of studies explored whether the drug might influence the duration and severity of the common cold. Findings were mixed regarding a statistically significant effect on duration across all studies.

  • Symptom Relief: Specifically, a meta-analysis of five double-blind, randomized controlled trials (RCTs) reported an association with changes in patient-reported symptom scores compared to placebo. This observed effect was seen across all age groups studied.
  • Research focus on Fever: Studies have examined the effect on reducing fever, with changes reported in some studies. Other research has explored whether the drug might influence headache and muscle aches, which are frequently reported with flu.

Studies on Combination Therapy (Drug X and Drug Y)

Studies investigated whether the combination of Drug X and Drug Y had a different outcome than other treatments in relation to viral load. Research focused on the antiviral properties of this combination.

  • Dosing and Timing: Clinical trials evaluated whether taking the combination within the first 48 hours of symptoms influenced the results. The combination was studied in comparison to monotherapy of Drug X alone. The evidence remains limited to patients with documented influenza infection.

Specific Populations and Research Data

Studies have also examined the use of the drug in certain patient groups:

  • Elderly Patients: Research has explored whether dose adjustments are needed, but current data do not suggest a difference in observed study outcomes compared to younger adults.
  • Patients with Liver Impairment: Research involving individuals with mild to moderate liver impairment has been conducted, but evidence remains limited for individuals with severe impairment.

Frequently Asked Questions (FAQ)

Common questions about Dexafort (FAQ)

Q: How quickly can a person expect Dexafort to start working?

A: Official product information indicates that the rapid-acting component of the dual-ester formulation is designed for a fast onset of activity. However, the onset of the full anti-inflammatory effect for this type of medication may take a few hours to become noticeable. The total duration of the effect is then prolonged by the second ester component.

Q: How is Dexafort different from over-the-counter anti-inflammatory drugs?

A: According to the official product information, Dexamethasone, the active ingredient, is a potent synthetic corticosteroid (glucocorticoid). This class differs from Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) because it achieves its powerful effect by influencing the body’s metabolic and immune responses, which is a different mechanism than how NSAIDs function.

Q: Does Dexafort treat pain directly or only inflammation?

A: The primary classification of Dexamethasone is as an anti-inflammatory and immunosuppressive agent. Official information indicates its main role is to powerfully reduce swelling and inflammation. The reduction of pain or discomfort is generally thought to occur as the underlying inflammatory process is suppressed.

Q: Is there a generic version of the drug equivalent to Dexafort?

A: The active substance, Dexamethasone, is widely available as a generic drug. However, Dexafort is a proprietary formulation that combines two specific Dexamethasone esters for both rapid and prolonged action. Due to this unique combination, a directly equivalent generic copy may not be available in all markets.

Q: Is it necessary to take Dexafort with food or on an empty stomach?

A: Regulatory information notes that Dexafort is an injection, meaning specific food intake rules do not apply to its administration route. However, for Dexamethasone medications taken orally (e.g., in tablet form), it is typically suggested that they be taken with food or milk. This may help in reducing the potential for stomach irritation.

Q: Is it common for people to experience weight gain while taking Dexafort?

A: Weight gain is a frequently reported side effect associated with Dexamethasone use. Official information indicates this effect is more common with long-term use and can be related to both fluid retention and an increase in appetite.

Q: Can Dexafort affect a person’s quality of sleep?

A: Yes, sleep disturbances and insomnia (difficulty sleeping) are documented side effects of Dexamethasone therapy, as noted in patient information leaflets.

Q: What are the known long-term side effects associated with Dexafort use?

A: Regulatory documents state that prolonged use of Dexamethasone is associated with several serious effects. These risks may include a higher risk of developing eye problems (such as cataracts or glaucoma), reduced bone density (osteoporosis), and changes in the body related to adrenal gland suppression.

Q: Does Dexafort have any effect on a person's mood or emotional state?

A: Yes, neuropsychiatric disturbances, which can include changes to mood, anxiety, depression, or euphoria, are documented as potential side effects. These effects are generally associated with the initiation of corticosteroid therapy.

Q: Can Dexafort cause an increase in appetite?

A: An increased appetite is one of the frequently reported side effects of Dexamethasone use, according to regulatory documents.

Q: Are there specific warnings for older adults (over 65) taking Dexafort?

A: While research evidence did not suggest a need for different dosing, official warnings advise that older patients should be treated with caution. This is because they may have a higher risk of experiencing certain side effects, such as reduced bone density or complications from fluid retention.

Q: What over-the-counter medicines or supplements are known to interact with Dexafort?

A: Regulatory information indicates a high-risk interaction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) due to the potential for increased risk of gastrointestinal ulcers. Additionally, any medication or supplement that affects the CYP3A4 enzyme system in the liver may interact and alter the level of Dexamethasone in the body.

Q: What are the guidelines on stopping treatment with Dexafort?

A: Regulatory documents advise that Dexamethasone not be stopped suddenly without professional oversight. Abrupt discontinuation carries a risk of withdrawal symptoms or acute adrenal insufficiency. The dose is typically reduced gradually, a process called tapering.

Q: What medical tests are often required for monitoring Dexafort's long-term use?

A: Monitoring for long-term use often involves checking blood pressure and blood glucose levels. Additionally, periodic examinations by an ophthalmologist (eye doctor) may be recommended to assess for potential cataracts or glaucoma.

Q: What are the signs of a serious or severe reaction to Dexafort that require attention?

A: Signs of a serious reaction described in patient information include symptoms of high blood sugar (like excessive thirst or urination) or symptoms of gastrointestinal bleeding (such as passing black or tarry stools). Signs of adrenal gland problems, such as severe, persistent weakness, are advised to be reported promptly.

Q: What is the purpose of taking Dexafort in the morning, as described in some sources?

A: Dexamethasone, when used in single-day or oral dosing, is often recommended to be taken in the morning. This practice is based on the goal of aligning the medication's effects with the body’s natural cortisol cycle. Taking it in the morning is generally thought to help minimize sleep disturbances.

Q: Does Dexafort use carry a risk for eye problems, such as cataracts or glaucoma?

A: Yes, official information confirms that long-term or repeated corticosteroid use, including Dexamethasone, is associated with a risk of developing eye problems. These risks include the formation of cataracts and the development of glaucoma, which is an increase in pressure inside the eye.

Q: Is there a maximum amount of time a person can generally take Dexafort?

A: Regulatory documents define Dexamethasone use by short-term (acute) versus long-term (chronic) treatment. While there is no universal maximum duration, high doses are generally limited to short periods (e.g., a few days), and prolonged use is cautioned against due to the risk of serious side effects.

Q: Why is it recommended to wear a medical alert while on Dexafort long-term?

A: The recommendation to wear a medical alert stems from the risk of adrenal gland suppression with long-term use. This alerts medical professionals that the body may not be able to naturally respond to physical stress (like injury or surgery) and may require supplemental medication in an emergency.

Q: Does Dexafort cause changes to the appearance of the face or body shape?

A: Yes, the development of Cushingoid features is a documented long-term side effect of corticosteroids. This includes changes such as the rounding of the face, often called a 'moon face,' and the abnormal accumulation of fat on the neck and trunk.

Q: What is the evidence regarding Dexafort's use for chronic conditions versus acute flare-ups?

A: Official regulatory documents indicate Dexamethasone injection is often used for conditions requiring a rapid response. It is frequently described as suitable for the treatment of acute disorders and is typically reserved for short-term intensive therapy in cases of severe inflammation.

Q: Does Dexafort need to be avoided before any type of surgery, including dental procedures?

A: Regulatory guidance suggests that patients inform their doctor or dentist about current or recent steroid use before any surgery, including dental procedures. This disclosure is a key precaution due to the potential for adrenal gland suppression caused by the medication.

Q: What precautions are advised regarding exposure to sick individuals while taking Dexafort?

A: Official patient information suggests caution regarding exposure to certain infections, particularly serious viral infections like chickenpox or measles. It is advised that exposure be reported to a healthcare provider promptly.

Q: Is there a known interaction between Dexafort and herbal remedies like St. John's Wort?

A: While specific herbal remedies are not always named, official documents warn about the category of medications that induce the CYP3A4 enzyme system. St. John's Wort is known to be an inducer in this system, which could potentially reduce the effectiveness of Dexamethasone by speeding up its clearance from the body.

Q: Can a person taking Dexafort generally drive or operate machinery?

A: Official patient information indicates that side effects such as dizziness, confusion, or visual changes (like blurred vision) may occur. If these or other adverse reactions affect concentration or coordination, it is generally suggested that a person avoid operating machinery or driving.

Q: What should a person do if they suspect an interaction between Dexafort and another drug?

A: Regulatory guidance suggests that if an interaction or adverse reaction is suspected, one should seek professional medical advice or contact their prescribing healthcare provider promptly.

Q: Is Dexafort used as a primary or adjunctive treatment for its approved uses?

A: Dexamethasone is frequently used as a supportive or adjunctive (add-on) component of treatment in many approved conditions. Official descriptions often refer to it being used in combination with other medications or as a means of controlling the body's response to an underlying illness.

Q: What is the common misunderstanding about the difference between Dexafort and cortisone shots?

A: Cortisone is a naturally occurring glucocorticoid, whereas Dexamethasone is a synthetic, man-made version. Regulatory texts describe Dexamethasone as a significantly more potent anti-inflammatory agent. Dexamethasone also differs by having minimal mineral-retaining properties compared to natural cortisone derivatives.

How should Dexafort be stored and disposed of?

The storage and disposal of Dexafort (Dexamethasone dual-ester suspension) must strictly adhere to the conditions mandated by official regulatory documents.

Storage Requirements

Condition Regulatory Rule
Temperature Limit Must not be stored above 25 °C (seventy-seven degrees Fahrenheit).
Light Protection Store the container in the outer carton to protect the product from light.
Container Handling Store the container in an upright position.
Child Safety Must be kept out of the sight and reach of children.

Stability and Disposal

The product's stability is defined post-use; the shelf life after first opening the immediate packaging (broaching the vial) is 28 days.

Disposal of any unused or expired product and waste material derived from it must be carried out in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dexafort found in:

A-Z Index: